Geneva, May 20 -- International Clinical Trials Registry received information related to the study (ISRCTN99030459) titled 'HMB to improve functional status in people with liver cirrhosis' on May 8.
Study Type: Interventional
Study Design:
Double-blind randomized placebo-controlled trial (Safety, Efficacy)
Primary Sponsor: University Hospitals Plymouth NHS Trust
Condition:
Advanced liver cirrhosis
Digestive System
Intervention:
Current interventions as of 09/05/2025:
Intervention: 3 g of HMB (nutritional supplement) daily for 12 weeks, oral administration of to 2 x 750 mg capsules twice daily
Matched placebo (maltodextrin)
Randomisation is via an online tool
Follow-up is 24 weeks post-baseline (12 weeks post-treatment).
Pre...